Table 2. Study follow-up and virologic outcomes Suppressed & high CD4 (VL <50, CD4 ≥350) N = 37 Suppressed & low CD4 (VL <50, CD4 <350) N = 29 Viremic & high CD4 (VL ≥50, CD4 ≥350) N = 54 Viremic & low CD4 (VL ≥50, CD4 <350) N = 61 Follow-up Total months on FTR, median (IQR) 12 (6, 16) 11 (6, 18) 12 (8, 17) 12 (8, 22) ≥180 days on FTR, n (%) 29 (78) 23 (79) 48 (89) 53 (87) ≥365 days on FTR, n (%) 17 (46) 10 (34) 28 (52) 31 (51) 6-month viral load Viral load measured within 91-270 days after FTR start, n 28 20 40 38 Viral load <50 copies/mL if available, n (%) 24 (86) 18 (90) 19 (48) 12 (32) 12-month viral load Viral load measured within 271-455 days after FTR start, n 14 11 29 30 Viral load <50 copies/mL if available, n (%) 9 (64) 11 (100) 15 (52) 10 (33) IQR, interquartile range; mL, milliliters; N, number; VL, viral load Conclusions: In routine clinical care in the U.S., virologic response was maintained in suppressed individuals regardless of CD4 cell count at FTR start. However, virologic effectiveness was low in viremic individuals. While immunologic response varied across individuals, heavily treatment-experienced individuals with low CD4 counts (<350 cells/ µL) may benefit from immunologic improvements with FTR use. General conditions 1. I confirm that I previewed this abstract and that all information is correct. I accept that the content of this abstract cannot be modified or corrected after the submission deadline and I am aware that it will be published exactly as submitted.: Yes 2. I confirm that the submission of the abstract constitutes my consent to publication (e.g. conference website, programmes, other promotions, etc.). : Yes 3. I herewith confirm that the contact details saved in this system are those of the corresponding author, who will be notified about the status of the abstract. The corresponding author is responsible for informing the other authors about the status of the abstract.: Yes 4. I agree that all data provided may be used (saved, stored, processed, transmitted and deleted) in compliance with the privacy policy to provide the services described.: Yes 113
RkJQdWJsaXNoZXIy Mzc2ODc=